Deferasirox administration resulted in significant reductions in IL1, IL3, IL6, and TNF-α, pivotal mediators of chronic inflammation and dysregulated hematopoiesis in MDS (Figure 4). Here, IL3 is linked to myelodysplastic syndrome.